These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16565737)

  • 61. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
    Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
    J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
    Moore HC; Green SJ; Gralow JR; Bearman SI; Lew D; Barlow WE; Hudis C; Wolff AC; Ingle JN; Chew HK; Elias AD; Livingston RB; Martino S;
    J Clin Oncol; 2007 May; 25(13):1677-82. PubMed ID: 17404368
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party.
    De Giorgi U; Blaise D; Lange A; Viens P; Marangolo M; Madroszyk A; Brune M; Afanassiev BV; Rosti G; Demirer T
    Bone Marrow Transplant; 2007 Dec; 40(11):1045-8. PubMed ID: 17922037
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer.
    Sayer HG; Schilling K; Vogt T; Blumenstengel K; Issa MC; Mügge LO; Kasper C; Kath R; Höffken K
    J Cancer Res Clin Oncol; 2003 Jun; 129(6):361-6. PubMed ID: 12884031
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer.
    Bojko P; Welt A; Schleucher R; Borquez D; Scheulen ME; Vanhoefer U; Poettgen C; Stuschke M; Broelsch CE; Stamatis G; Wilke H; Seeber S; Harstrick A
    Bone Marrow Transplant; 2004 Oct; 34(7):637-43. PubMed ID: 15300229
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients.
    Isaacs C; Slack R; Gehan E; Ballen K; Boccia R; Areman E; Kramer R; Hayes DF; Herscowitz H; Lippman M
    Breast Cancer Res Treat; 2005 Sep; 93(2):125-34. PubMed ID: 16187232
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.
    Schröder CP; Wisman GB; de Jong S; van der Graaf WT; Ruiters MH; Mulder NH; de Leij LF; van der Zee AG; de Vries EG
    Br J Cancer; 2001 May; 84(10):1348-53. PubMed ID: 11355946
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.
    Egerer G; Goldschmidt H; Hensel M; Harter C; Schneeweiss A; Ehrhard I; Bastert G; Ho AD
    Bone Marrow Transplant; 2002 Oct; 30(7):427-31. PubMed ID: 12368954
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
    Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
    Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
    Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease.
    Wendland MM; Asch JD; Pulsipher MA; Thomson JW; Shrieve DC; Gaffney DK
    Am J Clin Oncol; 2006 Apr; 29(2):189-95. PubMed ID: 16601441
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
    Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
    Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
    Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.